NEW YORK, NY / ACCESSWIRE / May 9, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
U.S. Xpress Enterprises, Inc. (USX)
Class Period: Purchasers of common stock pursuant/and or traceable to the initial public offering completed in June 2018
Lead Plaintiff Deadline: May 10, 2019
The complaint alleges that the Offering Documents failed to disclose that: (1) a shortage of trucks was negatively impacting U.S. Xpress's dedicated division; (2) (a) certain shipping patterns had been performing differently than expected and, as a result, (b) utilization, driver retention and hiring were being negatively affected, and as a result, (c) U.S. Xpress's dedicated accounts, including one large account, were being negatively impacted; and as a result, (d) U.S. Xpress's OTR division was providing continued support to the dedicated division; (3) (a) U.S. Xpress failed to stay informed regarding two large liability events; and as a result (b) U.S. Xpress's insurance claim expense was understated; and (4) U.S. Xpress's cost per mile for driver wages and independent contractors was exceeding the Company's internal expectations.
Get additional information about the USX lawsuit: http://www.kleinstocklaw.com/pslra-1/u-s-xpress-enterprises-inc-loss-submission-form?id=1457&from=1
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Class Period: November 14, 2016 to February 28, 2019
Lead Plaintiff Deadline: May 13, 2019
The complaint alleges that throughout the class period Corbus Pharmaceuticals Holdings, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Corbus improperly changed the primary efficacy endpoint for the clinical study of its drug candidate, Lenabasum, after the results were unblinded to Corbus; (2) Corbus reported a one-sided p value, not the traditional two-sided p value normally reported in clinical trials, in an effort to conceal the fact that the study results did not have statistical significance; and (3) as a result, Corbus' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
Get additional information about the CRBP lawsuit: http://www.kleinstocklaw.com/pslra-1/corbus-pharmaceutical-holdings-inc-loss-submission-form?id=1457&from=1
Mueller Water Products, Inc. (MWA)
Class Period: May 9, 2016 to August 6, 2018
Lead Plaintiff Deadline: June 10, 2019
According to the complaint, Mueller Water Products, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the Company lacked adequate testing for product quality; (2) certain products with radio components were susceptible to fail prematurely; (3) as a result, the Company was reasonably likely to incur increased expenses, including warranty costs; (4) these costs would materially impact the Company's financial statements; (5) the Company lacked adequate internal controls over warranty costs and estimates; and (6) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Get additional information about the MWA lawsuit: http://www.kleinstocklaw.com/pslra-1/mueller-water-products-inc-loss-submission-form?id=1457&from=1
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: The Klein Law Firm
View source version on accesswire.com: